Background: To investigate the relationship between changes in serum PSA, palliative response and survival following systemic treatment for symptomatic hormone-refractory prostate cancer (HRPC).
Introduction
Hormone-refractory prostate cancer (HRPC) is a common, lethal and morbid disease. The median survival of patients with metastatic prostate cancer is only about 8-10 months after development of hormone resistance [1, 2] , and a primary aim of management is palliative symptom control. The dominant symptoms are pain from bone metastases and fatigue and the most important components of management have been optimization of analgesic medication, and local radiotherapy to dominant sites of bone pain. Unfortunately, in this predominantly elderly patient population there is often generalized pain and poor tolerance to narcotic medication, and it may be difficult to obtain effective pain control with acceptable side effects. These patients also have poor tolerance to cytotoxic chemotherapy, and until recently there has been little evidence to suggest palliative benefit from chemotherapy.
A randomized phase III clinical trial conducted in several Canadian institutions has shown evidence of palliative benefit from the use of simple well-tolerated chemotherapy, (mitoxantrone and prednisone) as compared to best supportive care and pcednisone alone [3] . The primary palliative endpoint of this trial was a twopoint decrease in pain as assessed by a six-point pain scale completed by patients (or complete loss of pain if 1+ or 2+ initially), without increase in analgesic medication, and maintained for two consecutive evaluations, at least three weeks apart. The secondary endpoint was a decrease of ^ 50% in use of analgesic medication without an increase in pain. The overall palliative response was 38% versus 21% favoring the combination arm. Palliative responses were more durable, and median time to symptomatic progression of all patients on the chemotherapy arm was more than double that of the prednisone alone arm (24 vs. 10 weeks, respectively) (P < 0.0001). There were also more frequent and more durable improvements in other aspects of quality-of-life (QoL) in patients randomized to receive mitoxantrone and prednisone (M+P) [4] .
A second randomized phase III trial has also compared the use of mitoxantrone and steroid (hydrocortisone) to hydrocortisone alone in HRPC [5] . The chemo-therapy arm showed a greater probability of response, as measured by a fall in PSA, and improvement in the severity of pain (for those patients with pain at entry) as compared to the hydrocortisone alone arm. Neither trial has demonstrated a survival advantage to the chemotherapy arm [3, 5] . The FDA has approved the use of mitoxantrone (with a corticosteroid) for treatment of HRPC in the USA, the first pure chemotherapeutic drug approved for this purpose.
Many clinicians are using fall in serum PSA as a surrogate marker of disease shrinkage and of patient benefit when evaluating the effects of chemotherapy for patients with HRPC. However neither a reduction in PSA nor tumor shrinkage necessarily implies palliative benefit. The endpoint of 'response' that is used most commonly is a 50% decrease in PSA as compared to baseline, maintained for at least three or four weeks (the usual interval between courses of chemotherapy). However, other criteria for a PSA response are being used (e.g., >75%or > 90% decrease compared with baseline, and for varying time intervals) with lack of uniformity. A recent paper by Dawson reported the results of a questionnaire mailed to 35 prostate cancer experts and found that most investigators favored a definition of a PSA response as a greater than 50% decrease, for a minimum of 4 weeks [6] . That paper also revealed substantial disagreement on how those experts defined an increasing PSA level, and the duration of a PSA response [6] . A recent NCI workshop has proposed guidelines for using serum PSA as a marker of anti-tumor activity [7] .
For anti-cancer drugs which cause substantial sideeffects, there is likely to be poor correlation between palliative benefit and falling PSA, even if the latter is a reflection of decreasing tumor bulk. Also, some drugs may inhibit or up-regulate the synthesis or release of PSA from tumor cells without killing them [8, 9] . Hence even for well tolerated anti-cancer drugs it is unclear whether decreasing PSA values accurately reflect palliative benefits [2, 10] . An analysis has been published about the predictive value of a decrease in PSA of 50%, at eight weeks after commencement of therapy in two phase II trials of estramustine and etoposide, using the landmark analysis in a cohort of 62 men [11] . The authors concluded that a decrease in PSA was predictive of survival (P -0.0005) and of response in soft tissue lesions (P = 0.037) [11] . Scher et al. have published recently on 254 patients and concluded that a post-therapy decline in PSA of at least 50% was a significant factor predicting for survival at both 8 and 12 weeks (P = 0.002 and P -0.0012, respectively) using multivariate analysis and the landmark technique [12] . Unfortunately, patients were not evaluated for palliative benefit in these studies.
From the Canadian trial there is a substantial database of 161 patients who underwent serial palliative assessments at three weekly intervals during treatment, and compliance with quality of life questionnaires was about 90%. Evaluation of PSA was not an a priori requirement of the trial, but the majority of patients had multiple estimates of serum PSA. Initial analysis of this trial showed a weak association of PSA response with palliation, but many PSA data were not available at the time of this analysis since they were not submitted on case-report forms. In the present study, we have reexamined charts and computer data-bases of laboratory values for patients treated in the Canadian trial. Our aim was to perform a retrospective hypothesis-generating analysis to explore the relationship between changes in serum PSA, palliative response and survival following treatment of patients with symptomatic HRPC.
Specific hypotheses that were established prior to the present analysis were as follows:
(i) That a decrease in PSA after commencement of treatment with mitoxantrone and/or prednisone predicts a palliative response. (ii) That a rise in PSA after an initial PSA response predicts worsening symptoms, both after initiation of treatment and after an initial palliative response. (iii) That a decrease in PSA after initiation of treatment with mitoxantrone and/or prednisone predicts longer survival.
Patients and methods
Analyses of QoL and of changes in PSA were undertaken for the 161 patients with symptomatic HRPC who were randomized in the Canadian trial to receive M + P, or prednisone alone (P). PSA response was defined as a > 50% decrease compared to baseline maintained on at least two consecutive visits, each measurement being at least three weeks apart. We used three weeks as the minimum time interval between measurements, as that was the interval at which patients either received successive courses of chemotherapy, or had ongoing evaluation if on prednisone alone. The time to PSA response was defined as the time from start of treatment to the first of two or more PSA values that were ^50% lower than baseline. The duration of PSA response was defined as the interval from this time until the last PSA value that was ^ 50% lower than baseline. Primary PSA nonresponders were defined by two or more subsequent values of at least 25% above baseline. For purposes of comparison with palliative response, stable PSA was defined when neither a PSA response nor a primary PSA non-response occurred; this is not regarded as a criterion of anti-tumor activity.
Palliative response was defined by the primary and secondary endpoints of the trial (see introduction). Criteria for palliative response also had to be satisfied on two evaluations three or more weeks apart, and in the present analysis the start and end of palliative response were defined, respectively, as the date of initial response and of the last assessment for which response criteria were satisfied. This definition is consistent with PSA response, but differs from that in the primary report of the trial [3] where only patients satisfying the primary criterion of palliative response were considered, and start of response was dated from the time of first treatment.
We assessed also in the cohort of patients who achieved a PSA response, whether a subsequent increase in PSA was predictive of symptomatic worsening. A rising PSA after response was defined as the second of two consecutive increases in the PSA from the nadir, both values being greater than 1 25 times the nadir value. We delineated the time interval between this subsequent rise in PSA, and time of symptomatic worsening, regardless of which occurred first. Worsening symptoms were defined by (l) an increase in the present pain intensity of ^ I point compared with the nadir value of present pain intensity, without a decrease in analgesic score of 25% or more over the same time period, maintained on two consecutive occasions, or (ii) a 25% increase in analgesic score compared with the nadir value of analgesic score without a decrease in present pain intensity maintained on two consecutive occasions.
A specific analysis of patients treated at Princess Margaret Hospital, Toronto, (n = 33, 20% of the cohort) in which there was discordance between the direction of PSA change and symptoms, was undertaken to ascertain if there were explanations other than tumor progression, (e.g., a mechanical event), to account for the discrepancy.
Statistical methods
The sample size used for the present study was not based on pre-study considerations of statistical power, but on available PSA data after a re-examination of charts and computer bases of laboratory values for patients treated in the Canadian trial Proportions between the two treatment groups were compared using the Chi-square test with continuity correction. Patients were analyzed based on the intention-to-treat principle (and prior to crossover that was allowed in the prednisone arm, see below).
The association between PSA response and survival was described graphically using the Kaplan-Meier estimate in a univanate setting by applying the landmark method [13] . A landmark analysis was used to avoid the bias favoring the responders (the length bias) associated with a time-dependent variable. Time zero for this analysis was chosen a priori as nine weeks to correspond to the time when patients were being considered for their fourth cycle of chemotherapy. Outcome differences between those with and without a PSA response at the landmark time were compared using the log-rank test.
The association between PSA response and palliative response, and PSA response and survival were tested using the logistic regression model and the Cox proportional hazards model respectively. The model was evaluated for the effects of the following baseline variables: Eastern Cooperative Oncology Group (ECOG) performance status [14] (0, 1, 2, 3), age (continuous), hemoglobin (continuous), pain score (0, 1, 2, 3, 4), alkaline phosphatase (continuous) and serum PSA (continuous), and for the variable PSA response (yes/no). Virtually all patients had baseline ECOG performance scores, pain score and hemoglobin recorded, but eight patients were missing baseline data for alkaline phosphatase and five patients were missing baseline PSA. The analysis was performed only for those subjects that had complete data.
All statistical tests were two sided and all statistical analyses were produced using SAS software. The Kaplan-Meier plot was produced in S-Plus.
Results
One hundred sixty-one patients were entered in the Canadian trial between August 1990 and April 1994, and were randomized to receive M + P (n -80) or P alone (n = 81). The patients were well matched for baseline characteristics although there was a trend for more of the M+P patients to be treated with flutamide [3] . The median age was 67 years in both groups, greater than 95% had bone metastases, and the median serum PSA was 168 ug/1 for M + P patients and 151 ug/1 for the P patients. The patients were quite symptomatic with global quality of life scores in the mid-range; they had pain and were taking analgesic medication at a median level equivalent to about 80 mg per day of oral morphine.
Crossover to the chemotherapy arm from the prednisone arm was allowed by the protocol if patients were not responding after at least six weeks of treatment with Abbreviations: M + P -mitoxantrone and prednisone: P -prednisone alone. P -0.001 Chi-square test. Phi coefficient = 0.28. prednisone alone. Fifty of the eighty-one (62%) of prednisone patients crossed over to the combined therapy arm. The median time to cross over was at commencement of their fifth cycle of chemotherapy (12 weeks, range 1.6-46 weeks). Three patients crossed over before the six-week interval because of rapid symptomatic progression of disease. For those patients who crossed over, PSA response and palliative response have been evaluated only until the crossover point.
After scrutiny of charts and computer databases, it was found that 156 patients (97%) had baseline values of serum PSA, and 126 patients (78%) had at least two additional determinations of serum PSA to enable an assessment of PSA response.
Among patients with baseline and at least 2 subsequent determinations of serum PSA, a PSA response occurred in 27 of 68 (40%) patients receiving M + P and 9 of 58 (16%) patients receiving P alone, (P = 0.006). The percent of the evaluable patients achieving an overall palliative response from the M + P, and P arms of the study was 43% and 28%, respectively. If an intent-to-treat analysis is used for all randomized patients (recognizing the bias that some patients with missing PSA data may have had early disease progression) the rates of PSA response were 34% and 11% {P = 0.001) respectively, while the rates of palliative response were those reported previously, i.e., 30/80 (38%) for M + P and 17 of 81 (21%) for P (P = 0.025) [3] . Table 1 shows the overall relationship between PSA response and palliative response by treatment arm (P -0.001 by Chi-square test, phi coefficient = 0.28). There was a statistically significant association between PSA response and palliative response, but the strength of the association measured by the phi coefficient was relatively weak. Eighteen of the thirty (60%) patients treated with M + P that achieved a palliative response also obtained a PSA response. In contrast, for the prednisone-treated group, only 1 of 17 (6%) patients that achieved a palliative response also obtained a PSA response. The positive predictive value of a PSA response for a palliative response in all patients was 19 of 36 (53%). Of the 45 patients who had a palliative response and were evaluable for PSA response, 19 (42%) had a PSA response, but 8 (18%) had a rising PSA. Table 2 shows the results of the univariate logistic regression model for the influence of baseline factors on palliative response. Better performance status, higher hemoglobin and lower alkaline phosphatase levels were found to be predictive for palliative response. Some of the odds ratios differ only marginally from unity, reflecting the continuous nature of the prognostic factors. It was not possible to evaluate PSA response by univariate analysis as in only 11 of 19 (58%) of the patients in which there was both a palliative response and a PSA response did the PSA response precede the palliative response. Due to the relatively low numbers of patients who attained a palliative response, the paucity of factors that were statistically significant in predicting for a palliative response by univariate analysis, and the potential danger of creating a model that overfitted the data, a multivariate analysis examining factors that predicted for palliative response was not performed.
The median time to achieve a PSA response was 46.5 days (range 21-224 days) and the median time to achieve a palliative response was 43 days (range 19-210 days). These median times are close to when patients were being considered for their third cycles of therapy. The median duration of overall palliative response was 17 weeks (range 3-50 weeks) and 7 weeks (range 3-49 weeks) for patients on the M + P and P arms, respectively. The data did not permit a meaningful analysis of the duration of PSA response, or of the temporal relationship between rising PSA and symptomatic progression for patients who achieved PSA response. As per trial protocol, once patients receiving mitoxantrone no longer satisfied criteria for palliative response [3] they could be 40 Month* fron Figure I . The survival curves of PSA responders versus all others independent of treatment arm using the landmark analysis method.
removed from the study, and pain, analgesic scores and serum PSA levels were no longer recorded. Of the 36 patients who achieved PSA response, only 6 went on to have a recorded PSA rise. Of the remaining 30 patients, 28 came off study still having a PSA response, and 2 died within 4 weeks after having a final PSA value that was still less than 50% of the baseline value. The median duration of PSA response (censored at last available PSA for the 30 patients who were still responding at study closure) was 15+ weeks (range 3+-56 weeks). Only 6 of 19 patients who achieved both palliative and PSA response had criteria to evaluate both a subsequent rise in PSA from the nadir and symptomatic progression. In three of these patients, PSA progression preceded symptomatic worsening, and in the other three patients symptomatic worsening occurred first. Figure 1 shows the survival curves of PSA responders versus all others that were evaluable for PSA response; these curves are plotted independent of treatment arm using the landmark analysis method with the landmark point at nine weeks. When this survival analysis was conducted, only two patients from the trial were still alive. Twenty-three of the thirty-six patients (64%) who achieved a PSA response had done so by nine weeks and for this sub-group the responders fared statistically better with respect to survival than all other patients (n = 102) (P = 0.009). Table 3 shows the results of the univariate analysis of the influence of PSA response, palliative response and baseline factors on time to death. There was a strong association of PSA response with prolonged survival (P = 0.0004), while the association of palliative response with survival was of borderline significance (P = 0.055). Baseline PSA was not prognostic. Multivariate analyses examining the relationship between prognostic factors and time to death were performed by including either PSA response or palliative response in a Cox proportional hazards model with baseline factors (Tables 4 and 5 ). These response parameters were not entered in the same multivariate analysis because of their strong correlation. Better ECOG performance status, higher hemoglobin and lower present pain intensity were associated with Abbreviations: see Table 3 .
TableS Multivariate prognostic factor analysis of baseline factors and palliative response with time to death. Abbreviations: see Table 3 .
prolonged survival, but baseline alkaline phosphatase was not. A PSA response was strongly associated with prolonged survival (P < 0.0001), while palliative response was not (/> = 0.11). Specific analysis of the 33 patients treated at Princess Margaret Hospital did not show any clear reasons, other than progressive disease, to account for worsening symptoms manifesting as either an increase in analgesic score, or an increase in present pain intensity. Careful scrutiny of the patient's charts did not reveal any mechanical factors, e.g., fractures related to trauma. One patient developed incidental cholecystitis, which may have explained a transient increase in either analgesic score or the present pain intensity, but there was a coexistent continuing increase in his serum PSA. Also his pain and analgesic score did not decrease after recovery from his cholecystectomy, indicative of progressive disease.
Discussion
In the Canadian trial palliative responses in metastatic hormone-refractory prostatic adenocarcinoma occurred in 38% of patients given mitoxantrone and prednisone using strict response criteria. It is useful for clinicians treating patients to know whether the simpler measure of a reduction in serum PSA is predictive of a palliative response. Many clinicians are using reduction in PSA as a surrogate for palliative benefit without clear evidence that it is valid. A fall in PSA usually (but not invariably) represents a decrease in tumor bulk, but when very toxic drugs are used, it is unlikely that a fall in serum PSA will be predictive of improved QoL. The Canadian trial used relatively non-toxic chemotherapy with mitoxantrone and prednisone, and allows examination of the relationship between PSA and palliative response under conditions where one might expect them to be correlated.
We have found from this trial that if a patient has a PSA response to therapy, then about half (53%) will also have a clear palliative benefit. The median time to achieve a PSA response was almost identical to the median time to attain a palliative response, and in individual patients PSA response did not consistently precede palliative response. Despite the fact that the majority of patients who achieved a palliative response also had a PSA response (Table 1) , there were also several patients who had useful palliation without a clear-cut PSA response, or even in the face of a rising PSA. Likewise, there were individual patients who had a PSA response but no relief of pain. No clear reasons were found for these divergent results. Since a goal of treatment is palliation it seems appropriate to use symptom control or improved QoL as the major criterion for continuing chemotherapy in patients with HRPC. A PSA response does not support continued therapy in the face of worsening symptoms.
In our analysis we have combined the two arms of the study to evaluate prognostic factors that predicted for PSA response, palliative response and overall survival. It is quite probable that the mechanism of action of prednisone is different from that of a chemotherapy drug such as mitoxantrone, and that steroids may palliate symptoms independent of an effect on the disease. However, it is also unclear how much of the palliative benefit provided by mitoxantrone is mediated through reduction in sites of disease. By combining the arms, we were able to achieve greater power to be able to define possible prognostic factors that predict for palliative response or survival.
Our results are similar to those of other investigators who have studied prognostic factors for patients with HRPC [2, 11, 12] . These investigators have pooled patients from several phase II clinical trials. In an analysis of 110 patients treated at Memorial Sloan Kettering Cancer Center on seven sequential protocols, baseline hemoglobin, alkaline phosphatase, lactate dehydrogenase, Karnofsky performance status and a ^ 50% decline in PSA were associated with survival, but not baseline PSA [2] . In this analysis less than half of the patients had bone-only disease, so they presumably reflected a highly selected population. Scher et al. have updated this experience [12] with 254 patients treated on 11 different protocols, using the landmark analysis at 12 weeks: failure to achieve a PSA decline of ^50%, elevated lactate dehydrogenase, lower baseline hemoglobin, and younger age all predicted for adverse survival [12] . Smith et al. used a landmark analysis to analyze 62 patients with HRPC treated with estramustine and etoposide; this analysis found that performance status, baseline hemoglobin and decrease in serum PSA were statistically significant factors in predicting for longer survival [11] .
In our analysis, a decrease in PSA of ^ 50% compared to baseline predicted for longer survival (Table 4) whereas palliative response did not. This was shown both using the landmark analysis of survival curves, with the cut-off period at nine weeks, and by multivariate analysis in which each type of response was evaluated together with baseline factors. This result does not necessarily imply a cause and effect relationship between PSA response and longer survival. There was no difference in survival between the two arms of the Canadian trial, despite significant differences in palliative and PSA response rates between the two arms, although the cross-over design may have prevented the detection of small differences in survival. However, the CALGB study, which sought to prevent cross-over, also found no difference in survival between mitoxantrone and hydrocortisone and hydrocortisone alone [5] . Unknown prognostic factors may influence both the probability of survival and the probability of PSA response.
